• Esperion Therapeutics entered a contingent value rights agreement tied to its merger, offering up to USD 100 million in aggregate milestone-based cash payments.
• Each CVR provides a contractual right to contingent cash payments, non-transferable except in limited cases.
• A supplemental indenture resets conversion terms for Esperion’s 5.75% Convertible Senior Subordinated Notes due 2030 following the merger.
• Post-closing, each USD 1,000 principal converts into USD 1,032.68 cash, 326.80 CVRs; no fractional CVRs issued.
• Conversion tied to the make-whole fundamental change pays USD 1,232.62 cash, 390.07 CVRs per USD 1,000 principal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-082926), on July 13, 2026, and is solely responsible for the information contained therein.